Fusion Pharmaceuticals Inc (FUSN)
21.45
-0.04
(-0.19%)
USD |
NASDAQ |
May 03, 16:00
21.44
-0.02
(-0.07%)
After-Hours: 20:00
Fusion Pharmaceuticals Enterprise Value: 1.618B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 1.618B |
| May 02, 2024 | 1.621B |
| May 01, 2024 | 1.615B |
| April 30, 2024 | 1.616B |
| April 29, 2024 | 1.614B |
| April 26, 2024 | 1.615B |
| April 25, 2024 | 1.614B |
| April 24, 2024 | 1.614B |
| April 23, 2024 | 1.615B |
| April 22, 2024 | 1.607B |
| April 19, 2024 | 1.602B |
| April 18, 2024 | 1.601B |
| April 17, 2024 | 1.600B |
| April 16, 2024 | 1.602B |
| April 15, 2024 | 1.603B |
| April 12, 2024 | 1.606B |
| April 11, 2024 | 1.610B |
| April 10, 2024 | 1.610B |
| April 09, 2024 | 1.612B |
| April 08, 2024 | 1.614B |
| April 05, 2024 | 1.607B |
| April 04, 2024 | 1.616B |
| April 03, 2024 | 1.609B |
| April 02, 2024 | 1.604B |
| April 01, 2024 | 1.601B |
| Date | Value |
|---|---|
| March 28, 2024 | 1.607B |
| March 27, 2024 | 1.605B |
| March 26, 2024 | 1.605B |
| March 25, 2024 | 1.595B |
| March 22, 2024 | 1.600B |
| March 21, 2024 | 1.597B |
| March 20, 2024 | 1.587B |
| March 19, 2024 | 1.595B |
| March 18, 2024 | 702.30M |
| March 15, 2024 | 647.25M |
| March 14, 2024 | 592.19M |
| March 13, 2024 | 605.75M |
| March 12, 2024 | 604.05M |
| March 11, 2024 | 598.97M |
| March 08, 2024 | 601.36M |
| March 07, 2024 | 600.56M |
| March 06, 2024 | 590.20M |
| March 05, 2024 | 638.02M |
| March 04, 2024 | 661.13M |
| March 01, 2024 | 756.77M |
| February 29, 2024 | 754.38M |
| February 28, 2024 | 773.51M |
| February 27, 2024 | 797.42M |
| February 26, 2024 | 809.37M |
| February 23, 2024 | 768.73M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-102.01M
Minimum
Aug 11 2022
1.621B
Maximum
May 02 2024
192.66M
Average
131.90M
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 262.06B |
| Landos Biopharma Inc | 31.80M |
| Perspective Therapeutics Inc | 1.055B |
| Acasti Pharma Inc | 2.708M |
| Aurinia Pharmaceuticals Inc | 378.91M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.18M |
| Total Expenses (Quarterly) | 28.28M |
| EPS Diluted (Quarterly) | -0.39 |
| Earnings Yield | -6.85% |
| Normalized Earnings Yield | -7.599 |